Internal Medicine, Hematology & Oncology · Memphis, TN
NPI
1326070277
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1588 Union Ave
Memphis, TN, 38104
Phone (901) 683-0055
Groups this clinician bills Medicare through
Medicare paid, 2024
$651K
35,912 services
Medicare patients, 2024
573
Average age 74
Drug cost, 2024
$8.1M
2,408 prescriptions
Company payments, 2025
$1,372
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jarvis D Reed was code J9271 (injection, pembrolizumab, 1 mg), 4,000 times for 12 patients. In total Jarvis D Reed billed 35,912 services in 162 codes, and Medicare paid $651K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 4,000 | 12 | $44.68 | $179K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2,780 | 14 | $2.37 | $6,588 |
| 85025 Blood Count | Office | 817 | 240 | $7.51 | $6,134 |
| 80048 Clinical Chemistry | Office | 677 | 223 | $8.12 | $5,499 |
| 36415 Venipuncture Blood Collection | Office | 657 | 189 | $8.52 | $5,599 |
| 80076 Clinical Chemistry | Office | 614 | 222 | $7.87 | $4,834 |
| 99214 Office E&M - Established | Office | 494 | 313 | $76.17 | $38K |
| 83550 Clinical Chemistry | Office | 398 | 181 | $8.48 | $3,373 |
| 83540 Clinical Chemistry | Office | 398 | 181 | $6.27 | $2,495 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 356 | 26 | $0.09 | $31.99 |
| 82784 Immunoassay | Office | 289 | 33 | $9.11 | $2,634 |
| 82728 Clinical Chemistry | Office | 262 | 149 | $13.17 | $3,450 |
| 83883 Clinical Chemistry | Office | 204 | 33 | $13.33 | $2,719 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 155 | 33 | $71.45 | $11K |
| 83615 Clinical Chemistry | Office | 130 | 68 | $5.79 | $752 |
By year: 2022 $305K for 19,750 services; 2023 $206K for 12,472 services; 2024 $651K for 35,912 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 817 | 240 | $7.51 | $6,134 |
| 80048 Clinical Chemistry | 677 | 223 | $8.12 | $5,499 |
| 36415 Venipuncture Blood Collection | 657 | 189 | $8.52 | $5,599 |
| 80076 Clinical Chemistry | 614 | 222 | $7.87 | $4,834 |
| 83550 Clinical Chemistry | 398 | 181 | $8.48 | $3,373 |
| 83540 Clinical Chemistry | 398 | 181 | $6.27 | $2,495 |
| 82784 Immunoassay | 289 | 33 | $9.11 | $2,634 |
| 82728 Clinical Chemistry | 262 | 149 | $13.17 | $3,450 |
| 83883 Clinical Chemistry | 204 | 33 | $13.33 | $2,719 |
| 83615 Clinical Chemistry | 130 | 68 | $5.79 | $752 |
Medicare prescription drug claims, 2024
In 2024, the drug Jarvis D Reed prescribed most often to Medicare patients was Eliquis (Apixaban), with 145 prescriptions and refills. In total Jarvis D Reed wrote 2,408 Medicare prescriptions that cost $8.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 145 | 215 | 43 | $126K |
| Letrozole Generic | 141 | 288 | 34 | $2,422 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 91 | 91 | 18 | $2,839 |
| Xarelto Rivaroxaban | 81 | 120 | 18 | $68K |
| Revlimid Lenalidomide | 77 | 77 | 12 | $1.4M |
| Lenalidomide Generic | 75 | 75 | Under 11 | $1.0M |
| Gabapentin Generic | 74 | 92 | 15 | $739 |
| Potassium Chloride Generic | 72 | 121 | 30 | $1,737 |
| Dexamethasone Generic | 67 | 91 | 26 | $1,841 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 66 | 66 | 20 | $1,847 |
| Warfarin Sodium Generic | 64 | 101 | Under 11 | $645 |
| Xtandi Enzalutamide | 60 | 60 | 11 | $721K |
| Levothyroxine Sodium Generic | 58 | 103 | 16 | $427 |
| Prochlorperazine Maleate Generic | 55 | 57 | 37 | $1,630 |
| Oxycodone Hcl Generic | 48 | 48 | Under 11 | $1,831 |
Brand drugs: 861 claims; generic drugs: 1,547 claims; opioid claims: 287.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jarvis D Reed $1,372 ($1,372 in general payments such as food, travel and fees) from 21 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $265.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 8 | $265 |
| Janssen Biotech, Inc. JNJ | 14 | $247 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $126 |
| Astellas Pharma US Inc 4503.T | 4 | $103 |
| GlaxoSmithKline, LLC. GSK | 5 | $90.98 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $61.29 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $58.95 |
| Celgene Corporation BMY | 2 | $55.38 |
| Merck Sharp & Dohme LLC MRK | 2 | $51.83 |
| Daiichi Sankyo Inc. 4568.T | 2 | $43.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.